RecruitingNot ApplicableNCT04562194
NeVa ONE Registry Study
NEVA ONE One-Pass Reperfusion With the NeVa Stent-Retriever EMEA Registry
Sponsor
Vesalio
Enrollment
600 participants
Start Date
Jul 1, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
A prospective, open label study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
Eligibility
Min Age: 18 Years
Inclusion Criteria11
- Only subjects already treated with the NeVa thrombectomy devices can be considered for enrollment.
- Age ≥18
- NIHSS score ≥ 6
- Pre-stroke mRS score ≤ 1
- Intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery (PCA), basilar artery, or vertebral artery demonstrated with DSA.
- Thrombectomy procedure can be initiated within 24 hours from symptom onset (defined as time last known well \[TLKW\])
- The patient should have confirmed LVO and salvageable penumbra. Any automated software for determine the volume of viable tissue is acceptable. patient selection should follow the following guidelines:
- ASPECTS 6-10 if treatment started 0-6 hours from TLKW
- ASPECTS 8-10 if treatment started 6-24 hours from TLKW
- Ischemic core ≤ 50 cc
- Subject or legal representative is able and willing to give informed consent within 72 hours after the intervention (may use independent physician consent in this timeframe and gain subject or legal representative consent later than 72 hours).
Exclusion Criteria13
- Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept).
- Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre- treatment pulmonary aspiration.
- Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories
- Cerebral vasculitis
- History of severe allergy to contrast medium.
- Known allergy to NeVa materials (nitinol, stainless steel)
- Suspicion of aortic dissection, septic embolus, or bacterial endocarditis
- Systemic infection
- Significant mass effect with midline shift
- Evidence of intracranial tumor (except small meningioma)
- Inability to deploy NeVA device for at least one pass for any other reason
- Life expectancy less than 6 months
- Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICENeVa Stent Retriever
mechanical neurothrombectomy
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04562194
Related Trials
REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)
NCT075999041 location
rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window
NCT076068071 location
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT0569124455 locations
Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial
NCT053269321 location
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302242 locations